Quetmolimab - EA Pharma

Drug Profile

Quetmolimab - EA Pharma

Alternative Names: E6011; KANAb 001

Latest Information Update: 01 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KAN Research Institute
  • Developer EA Pharma; Eisai Co Ltd
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Chemokine CX3CL1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary biliary cirrhosis; Rheumatoid arthritis
  • Phase I/II Crohn's disease

Most Recent Events

  • 03 Oct 2018 E A Pharma plans a phase II trial for Crohn's disease in Japan, Poland, Czech Republic and Hungary in October 2018 (JapicCTI-184139)
  • 24 Jun 2018 Biomarkers information updated
  • 13 Jun 2018 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top